Novavax stock

Novavax Begins Human Testing For Covid-19 Vaccine, Expects Results ...

Making the world smarter, happier, and richer. Help (TMFFishBiz) Apr 1, 2020 at 7:04AM Author Bio Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Probably few people would have predicted a year ago that Novavax () would emerge as one of the After all, Novavax stock plunged nearly 90% in 2019.

It's a totally different picture for the biotech so far this year, though. While most stocks have stumbled due to worries about the coronavirus pandemic, Novavax's shares have soared. Nearly everything that could go right for Novavax has gone right in recent months. But should you buy Novavax stock right now?

Image source: Getty Images.

Multiple opportunities Novavax has multiple growth opportunities. The most promising one right now is its nanoparticle-based influenza vaccine NanoFlu.

The company from a late-stage study of NanoFlu in a head-to-head comparison against Sanofi's flu vaccine Fluzone Quadrivalent. I won't get into all of the details from that study, but suffice it to say that NanoFlu appeared to be more effective than Fluzone on several efficacy fronts with a similar safety profile.

Novavax will now move forward with preparations for a regulatory filing in the U.S. for NanoFlu. Analysts' peak sales estimates for the vaccine range from the ballpark of $550 million to around $1.7 billion if it gains FDA approval. Even on the low end of the projections, Novavax could have a big winner on its hands.

NanoFlu isn't the only candidate with significant potential in Novavax's pipeline. Even though respiratory syncytial virus (RSV) vaccine ResVax failed twice in late-stage clinical studies, it . Novavax still thinks the experimental vaccine could improve the concentration of oxygen in the blood of infants and reduce hospitalizations linked to RSV lower respiratory tract infection in infants via maternal immunization. The biotech is in talks with regulatory agencies and potential partners on ways to bring ResVax to market.

Novavax is also in the race to develop a novel coronavirus vaccine. The company won funding from the Coalition for Epidemic Preparedness Innovations (CEPI) to develop and conduct an early stage clinical study for a nanoparticle-based COVID-19 vaccine. Novavax is currently evaluating several vaccine candidates and plans to advance the most promising one to testing in humans by May or June.

Multiple risks, too Like any clinical-stage biotech, Novavax has plenty of risks to go along with its opportunities. Probably the biggest risk right now in terms of the potential impact on the company is that NanoFlu could fail to win FDA approval. Around 11% of regulatory filings for infectious disease candidates wind up received a thumbs down from the FDA based on historical data compiled by the Biotechnology Innovation Organization.

Novavax would love to figure out a way to move ResVax forward without having to conduct another phase 3 clinical trial. However, the odds of that happening seem to be very low. Assuming the company initiates another late-stage study of the vaccine, there's a significant risk of flopping on the third try.

On the coronavirus vaccine front, Novavax could win and still lose. There's no guarantee that the biotech's experimental COVID-19 vaccine will prove to be both safe and effective. Even if it is, though, several other drugmakers are developing their own COVID-19 vaccines. Any of these other candidates could turn out to be better than Novavax's experimental vaccine.

Another risk for Novavax relates to its financial position. The company reported cash, cash equivalents, marketable securities, and restricted cash totaling $82.2 million as of Dec. 31, 2019. Novavax subsequently raised another $156 million. It's expensive to launch a new product. Should the company win FDA approval for NanoFlu, it could very well need to issue more shares to fund commercialization, which would result in the dilution in the value of existing shares.

To buy or not to buy? I like Novavax's chances of success with NanoFlu. With Novavax's market cap currently around $700 million, my view is that the overall potential for NanoFlu hasn't been fully priced into the biotech's share price. And while I'm not as optimistic about Novavax's ResVax and COVID-19 programs, they still represent the potential for additional future growth for the company.

Risk-averse investors will probably be better off staying away from like Novavax that don't have any approved products. My view, though, is that aggressive investors should consider buying a small stake in Novavax. I think Novavax still has plenty of room to run if NanoFlu wins FDA approval.

10 stocks we like better than Novavax When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the for investors to buy right now… and Novavax wasn't one of them! That's right -- they think these 10 stocks are even better buys.

*Stock Advisor returns as of April 16, 2020

has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a .

----------------------------------------------------------------------------------------------------------------------------------

Motley Fool Returns Stock Advisor S&P 500 410% 88% Stock Advisor launched in February of 2002. Returns as of 05/27/2020.

Cumulative Growth of a $10,000 Investment in Stock Advisor Calculated by Time-Weighted Return ----------------------------------------------------------------------------------------------------------------------------------

Stocks Novavax $48.17 up $2.06 (4.47%) Sanofi $47.27 down $0.03 (-0.06%)

----------------------------------------------------------------------------------------------------------------------------------

Related Articles

----------------------------------------------------------------------------------------------------------------------------------

[//b.scorecardresearch.com/p?c1=2&c2=17054958&cv=2.0&cj=1][https://www.facebook.com/tr?id=1561515534098628&ev=PageView&noscript=1] Quantcast [//pixel.quantserve.com/pixel/p-p4jUuewM-vyu5.gif?labels=_fp.event.Default] Quantcast [//pixel.quantserve.com/pixel/p-p4jUuewM-vyu5.gif?labels=_fp.event.Default] [//trc.taboola.com/1008198/log/3/unip?en=page_view][https://q.quora.com/_/ad/e2f4cee7b1d3457da6cceb16018039ee/pixel?tag=ViewContent&noscript=1] [https://trc.taboola.com/1250763/log/3/unip?en=page_view] [https://trc.taboola.com/1250760/log/3/unip?en=page_view] [https://trc.taboola.com/1250761/log/3/unip?en=page_view] [https://trc.taboola.com/1250762/log/3/unip?en=page_view][https://analytics.twitter.com/i/adsct?txn_id=nuo4p&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0][//t.co/i/adsct?txn_id=nuo4p&p_id=Twitter&tw_sale_amount=0&tw_order_quantity=0] Novavax Jumps After Starting Covid-19 Vaccine Study - Bloomberg

Novavax Jumps After Starting Covid-19 Vaccine Study - Bloomberg

As you were browsing www.marketwatch.com something about your browser made us think you were a bot. There are a few reasons this might happen:

After completing the CAPTCHA below, you will immediately regain access to www.marketwatch.com. Novavax Starts Covid-19 Study and Targets First Results in July ...

Novavax Starts Covid-19 Study and Targets First Results in July ...

Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent a broad range of infectious diseases. Using innovative proprietary recombinant nanoparticle vaccine technology, we produce vaccine candidates to efficiently and effectively respond to both known and emerging disease threats. Our vaccine candidates are genetically engineered three-dimensional nanostructures that incorporate recombinant proteins critical to disease pathogenesis.

Product Pipeline Our product pipeline targets a variety of infectious diseases, with clinical vaccine candidates for respiratory syncytial virus (RSV), seasonal influenza and Ebola virus (EBOV) and a preclinical program for a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

Corporate Overview Novavax is headquartered in Gaithersburg, Maryland with additional facilities in Uppsala, Sweden. Novavax is traded on the Nasdaq Stock Market under the symbol NVAX and is dedicated to developing novel vaccines to address infectious disease.

All Articles

Novavax stock

More articles: